0001640334-16-001576.txt : 20160818 0001640334-16-001576.hdr.sgml : 20160818 20160818145620 ACCESSION NUMBER: 0001640334-16-001576 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 37 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160818 DATE AS OF CHANGE: 20160818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOADAPTIVES, INC. CENTRAL INDEX KEY: 0001575142 STANDARD INDUSTRIAL CLASSIFICATION: BLANK CHECKS [6770] IRS NUMBER: 462592228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-54949 FILM NUMBER: 161840806 BUSINESS ADDRESS: STREET 1: 1015 S CIMARRON RD CITY: LAS VEGAS STATE: NV ZIP: 89145 BUSINESS PHONE: (702) 560-1632 MAIL ADDRESS: STREET 1: 1015 S CIMARRON RD CITY: LAS VEGAS STATE: NV ZIP: 89145 FORMER COMPANY: FORMER CONFORMED NAME: APEX 8 Inc. DATE OF NAME CHANGE: 20130424 10-Q 1 bioadaptives_10q.htm 10-Q bioadaptives_10q.htm

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 

Form 10-Q

 

x Quarterly report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended June 30, 2016

 

¨ Transition report pursuant Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _______ to _______

 

000-54949

(Commission file number) 

 

BioAdaptives Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

46-2592228

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

1015 S. Cimarron Rd, Las Vegas NV

89145

(Address of principal executive offices)

(Zip Code)

 

(702) 560-1632

(Registrant's telephone number, including area code)

 

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes x No ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

¨

Accelerated filer

¨

Non-accelerated filer

¨

Smaller reporting company

x

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨No x

 

On August 18, 2016, 14,180,456 shares of the registrant's common stock were outstanding.

 

 

 
 
 

 

TABLE OF CONTENTS

 

PART I

 

 

 

Item 1.

Financial Statements

3

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

11

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

19

Item 4.

Controls and Procedures

19

 

 

 

PART II

 

 

 

 

Item 1.

Legal Proceedings

21

Item 1A.

Risk Factors

21

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

21

Item 3.

Defaults Upon Senior Securities

21

Item 4.

Mine Safety Disclosures

21

Item 5.

Other Information

21

Item 6.

Exhibits

22

Signatures

23

 

 
2
 

 

PART I – FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

BIOADAPTIVES, INC. 

CONSOLIDATED BALANCE SHEETS

 

 

 

June 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

 

 

(Unaudited)

 

 

 

 

ASSETS

 

 

 

 

 

 

Current Assets:

 

 

 

 

 

 

Cash

 

$100

 

 

$99

 

Inventory

 

 

144,402

 

 

 

-

 

Deposit

 

 

1,700

 

 

 

1,700

 

Marketable securities

 

 

2,855

 

 

 

4,864

 

Total Current Assets

 

 

149,057

 

 

 

6,663

 

 

 

 

 

 

 

 

 

 

Furniture and Fixtures, net

 

 

264

 

 

 

527

 

 

 

 

 

 

 

 

 

 

TOTAL ASSETS

 

$149,321

 

 

$7,190

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current Liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

9,645

 

 

 

34,354

 

Accrued liabilities - related party

 

 

34,361

 

 

 

25,361

 

Advance from Ferris Holding, Inc. - related party

 

 

252,987

 

 

 

150,849

 

Total Current Liabilities

 

 

296,993

 

 

 

210,564

 

 

 

 

 

 

 

 

 

 

Total Liabilities

 

 

296,993

 

 

 

210,564

 

 

 

 

 

 

 

 

 

 

Stockholders' Deficit:

 

 

 

 

 

 

 

 

Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)

 

 

-

 

 

 

-

 

Common stock ($.0001 par value, 100,000,000 shares authorized; 14,180,456 and 12,736,436 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively)

 

 

1,419

 

 

 

1,275

 

Additional paid-in capital

 

 

2,844,866

 

 

 

2,673,170

 

Accumulated other comprehensive income (loss)

 

 

(58,684)

 

 

(56,675)

Accumulated deficit

 

 

(2,935,273)

 

 

(2,821,144)

Total Stockholders' Deficit

 

 

(147,672)

 

 

(203,374)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

 

$149,321

 

 

$7,190

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
3
 

 

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) 

(Unaudited)

 

 

 

Three Months Ended June 30, 

 

 

Six Months Ended June 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenues

 

$-

 

 

$-

 

 

$-

 

 

$-

 

Cost of revenue

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Gross Margin

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Expenses

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Depreciation

 

 

132

 

 

 

132

 

 

 

263

 

 

 

264

 

General and administrative

 

 

24,428

 

 

 

95,725

 

 

 

100,592

 

 

 

108,332

 

Professional fees

 

 

8,645

 

 

 

13,500

 

 

 

13,274

 

 

 

30,031

 

Total Operating Expenses

 

 

33,205

 

 

 

109,357

 

 

 

114,129

 

 

 

138,627

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating Income (Loss)

 

 

(33,205)

 

 

(109,357)

 

 

(114,129)

 

 

(138,627)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Income (Expense)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest - related party

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(156)

Total Other Income (Expense)

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(156)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss

 

$(33,205)

 

$(109,357)

 

$(114,129)

 

$(138,783)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other Comprehensive Income (Loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) on marketable securities

 

 

(2,707)

 

 

(16,283)

 

 

(2,009)

 

 

(19,561)

Other Comprehensive Income (Loss)

 

 

(2,707)

 

 

(16,283)

 

 

(2,009)

 

 

(19,561)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive Income (Loss)

 

 

(35,912)

 

 

(125,640)

 

 

(116,138)

 

 

(158,344)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Loss Per Share: Basic and Diluted

 

$(0.00)

 

$(0.01)

 

$(0.01)

 

$(0.01)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Number of Shares Outstanding: Basic and Diluted

 

 

14,180,456

 

 

 

12,654,214

 

 

 

13,823,350

 

 

 

12,654,214

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
4
 

 

BIOADAPTIVES, INC. 

CONSOLIDATED STATEMENTS OF CASH FLOWS 

(Unaudited)

 

 

 

 Six Months Ended June 30,

 

 

 

2016

 

 

2015

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

Net loss

 

$(114,129)

 

$(138,783)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation

 

 

263

 

 

 

264

 

Stock-based compensation - related party

 

 

27,438

 

 

 

21,710

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

 

75,506

 

 

 

-

 

Accrued liabilities – related party

 

 

9,000

 

 

 

115,650

 

Net Cash Used In Operating Activities

 

 

(1,922)

 

 

(1,159)

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Advances from related party

 

 

4,873

 

 

 

-

 

Payment on advances from related party

 

 

(2,950)

 

 

(2,700)

Principal payments on related party debt

 

 

-

 

 

 

(34,000)

Net Cash Provided By (Used In) Financing Activities

 

 

1,923

 

 

 

(36,700)

 

 

 

 

 

 

 

 

 

Net change in cash

 

 

1

 

 

 

(37,859)

Cash at beginning of period

 

 

99

 

 

 

37,871

 

Cash at end of period

 

$100

 

 

$12

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTAL CASH FLOW INFORMATION:

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$-

 

 

$-

 

Cash paid for interest

 

$-

 

 

$902

 

 

 

 

 

 

 

 

 

 

NON CASH INVESTING AND FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

Settlement of liabilities by related party

 

$100,215

 

 

$-

 

Unrealized loss on investments in marketable securities

 

$2,009

 

 

$19,561

 

Purchase of inventory by common shares

 

$144,402

 

 

$-

 

 

The accompanying notes are an integral part of these unaudited consolidated financial statements.

 

 
5
 

 

BIOADAPTIVES, INC. 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS 

For the Six Months Ended June 30, 2016 

(Unaudited)

 

1. DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) ("BioAdaptives", "Company") was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.

 

On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc ("Blenders") in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.

 

On September 1, 2014, the Company entered into a License Agreement ("Agreement") with Ferris Holding, Inc. ("Ferris"). The Agreement gives the Company the right to use Ferris's proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

On September 1, 2014, the Company entered into a Sub-License Agreement ("Sub-License") with Essence International, Ltd. ("Essence"). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

 

2. SUMMARY OF SIGNIFICANT POLICIES

 

Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

 

 
6
 

 

In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

 

Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

 

Level 1

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2

Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

 

Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of June 30, 2016.

 

Fair Value Measurements as of June 30, 2016 Using:

 

 

 

Total Carrying Value as of

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

June 30, 2016

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Equity Securities

 

$2,855

 

 

$2,855

 

 

$-

 

 

$-

 

Total

 

$2,855

 

 

$2,855

 

 

$-

 

 

$-

 

 

Equity securities at June 30, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $2,855 ($0.027 per share).

 

 
7
 

 

Inventory

 

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at June 30, 2016, the Company determined that no reserve was required.

 

The inventory acquired during the period has been accounted for at consideration, which was based on the shares provided in the transaction to an entity under common control. Total consideration for the $144,402 of inventory resulted in the issuance of 1,444,020 common shares based on the value of $0.10 per share at the transaction date.

 

3. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $2,935,273 as of June 30, 2016. The Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

 

4. STOCKHOLDERS' EQUITY

 

Preferred Stock – The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of June 30, 2016 and December 31, 2015, no shares of preferred stock had been issued.

 

Common Stock – The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock. As of June 30, 2016 and December 31, 2015, there were 14,180,456 and 12,736,436 shares of the Company's common stock issued and outstanding, respectively.

 

On February 15, 2016, the Company issued 1,444,020 shares of common stock to Ferris Holding, Inc. a common control entity for the purchase of inventory valued at $144,402.

 

In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two years of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, $1.10 per share, which resulted in a total consideration of $110,050 which will be expensed throughout the two-year term of the employment agreement. For the six months ended June 30, 2016 and 2015, the Company expensed $27,438 and $21,710, respectively.

 

 
8
 

 

5. RELATED PARTY TRANSACTIONS

 

Advances from Ferris Holding, Inc., the controlling shareholder of the Company, are non-interest bearing, unsecured and due on demand. During the six months ended June 30, 2016, $100,215 was paid by Ferris Holding, Inc. on behalf of the Company and the Company received cash advance of $4,873 from Ferris Holding, Inc and repaid $2,950 to Ferris Holding. As of June 30, 2016 and December 31, 2015, the Company had advances from Ferris Holdings, Inc. – related party balance of $252,987 and $150,849, respectively.

 

On February 15, 2016, the sole member of the Board of directors of BioAdaptives adopted the following resolution and the President was authorized to negotiate the purchase of the below referenced products from Ferris Holding, Inc., an entity under common control and to pay for the products with the Company's common stock.

 

·

Ferris Holding Inc. has manufactured the following products for the Company: PrimiCellÒ, PrimiLiveÒ, PrimiTrimTM and Equine RegenÒPlus; and

 

·

The Company chooses to purchase the products for distribution by the Company

 

On February 15, 2016, the Company purchased inventory for $144,402 from Ferris Holding, Inc., the controlling shareholder of the Company. In accordance with ASC 805, the transaction is considered to be a transfer of assets under common control. The consideration for the inventory was the issuance of 1,444,020 of common shares at the rate of $0.10 per share on the date of the transaction. On August 11, 2016, the Company physically issued 1,444,020 shares of common stock.

 

On February 6, 2015, the Company entered into a two (2) year employment agreement with its chief executive officer, Christopher G. Hall, whereby the Company issued 100,000 shares of restricted common stock as compensation for two (2) years of executive services to be performed. The shares were valued at the closing share price of $1.10 on the date of the agreement. This resulted in compensation expense of $110,050 being amortized over the two (2) year term of the employment agreement. Compensation expense of $27,438 was amortized for six months ended June 30, 2016.

 

On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is $1,500. The term of the lease is month to month. As of June 30, 2016 and December 31, 2015, the Company has a rent payable due to Ferris in the amount of $34,361 and $25,361, respectively, which is included in our accrued liabilities – related party balance in our consolidated balance sheets.

 

6. SUBSEQUENT EVENT

 

On August 11, 2016, the Company physically issued 1,444,020 shares of common stock to Ferris Holding, Inc. for the purchase of inventory valued at $144,402.

 

 
9
 

 

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). We have based these forward-looking statements on our current expectations and projections about future events, and they are applicable on as of the dates of such statement. These forward-looking statements are subject to known and unknown risks, uncertainties and assumptions about us that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by such forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "forecast," "expect," "plan," anticipate," believe," estimate," continue," or the negative of such terms or other similar expressions. Factors that might cause or contribute to such a discrepancy include, but are not limited to, those listed under the heading "Risk Factors" and those listed in our other SEC filings. You should not put undue reliance on any forward-looking statements. These statements speak only as of the date of this Quarterly Report on Form 10-Q, even if subsequently made available on our website or otherwise, and we expressly disclaim any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this Quarterly Report on Form 10-Q. The following discussion should be read in conjunction with our Financial Statements and related Notes thereto included elsewhere in this report. Throughout this Quarterly Report on Form 10-Q we will refer to BioAdaptives, Inc., together with its subsidiaries, as "BioAdaptives," the "Company," "we," "us," and "our."

 

 
10
 

 

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

 

Overview

 

APEX 8 Inc. was incorporated in the State of Delaware on April 19, 2013. On May 3, 2013, we filed a registration statement on Form 10 to register with the U.S. Securities and Exchange Commission as a public company. We were originally organized as a vehicle to investigate and, if such investigation warranted, acquire a target company or business seeking the perceived advantages of being a publicly held corporation.

 

On June 21, 2013, our former sole officer and director, entered into a Share Purchase Agreement pursuant to which he sold an aggregate of 10,000,000 shares of his shares of the Company's common stock to Ferris Holding, Inc. at a purchase price of $40,000. In the aggregate, these shares represented 100% of the Company's issued and outstanding common stock. Effective upon the closing of the Share Purchase Agreement, our former sole officer and director owned no shares of the Company's stock.

 

Additionally, on June 21, 2013, the Company accepted the resignations of our former sole officer and director as the Company's President, Chief Executive Officer, Chief Financial Officer, Secretary and Chairman of the Board of Directors. These resignations were in connection with the consummation of the Share Purchase Agreement with Ferris Holding, Inc., and were not the result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices. Effective as of the same date, to fill the vacancies created by our former sole officer and director's resignations, the Company elected and appointed Barry K. Epling as Chairman of the Board of Directors, and Gerald A. Epling, as President, Chief Executive Officer, Secretary, Chief Financial Officer and Member of the Board of Directors of the Company.

 

Subsequently, on September 24, 2013, the Board of Directors and Majority Stockholder of the Company approved an amendment to the Company's Certificate of Incorporation to change the name of the Company from APEX 8 Inc. to BioAdaptives, Inc. On September 25, 2013, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the Secretary of State of the State of Delaware to change the name of the Company to BioAdaptives, Inc.

 

On July 14, 2014, the Company announced changes in its management. Gerald A. Epling, who had been serving as the Company's Chief Executive Officer, Chief Financial Officer and a Director, resigned from all positions. His resignation was in connection to pursue other interests, and was not the result of any disagreement with the Company on any matter relating to the Company's operations or practices. On that same day, the Company elected Barry Epling, who also serves as Chief Executive Officer, President and Director of Ferris Holding (FHI) to the positions vacated by Gerald Epling. As of the date of the event, FHI was the Company's controlling stockholder.

 

On February 6, 2015, the Company announced changes in its management. Barry Epling, who had been serving as the Company's President, Chief Executive Officer, Chief Financial Officer, and Secretary, resigned from his positions. He remains the Company's Chairman of the Board of Directors. His resignation was in connection to pursue other interests, and was not the result of any disagreement with the Company on any matter relating to the Company's operations or practices. One that same day, the Company elected Christopher G. Hall, as its President, Chief Executive Officer, Chief Financial Officer and Secretary. As of the date of the event, FHI was the Company's controlling stockholder.

 

Discussion

 

BioAdaptives Inc. is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages. Our base of intellectual property and products, which are patent pending solutions in the form of devices and nutraceuticals, are designed to aid in cognition, focus, fatigue reduction, increased testosterone, improved overall emotional and physical wellness, healing, and anti-aging.

 

 
11
 

  

The Company's strategy is to develop a position as a leader in supplying quality nutraceutical products to an aging population within developed countries such as the United States, Canada, Western Europe, Eastern Europe, and Russia, and in Asian countries such as China, Japan, Korea and Taiwan, while continuing to create new innovative, health inspired products to generate growth in sales and profitability. Some of the products have proven to be as effective or more effective on horses and dogs than on humans and this has caused us to expand the target market to include dogs and horses.

 

We can make no assurances that we will find commercial success in any of our products. We plan to rely upon our sales and licensing of our licensed Agronifier technology and direct and indirect sales of the P-3 and NutraLoadÒ products for revenues, neither of which have produced any significant revenue since our inception. We are a new company and thus have very limited experience in sales expectations and forecasting. We also have not fully discovered any seasonality to our business during the first quarter compared to any quarter in fiscal 2016.

 

COMPETITION

 

As a new entrant in the nutraceuticals market, we compete in an industry intensely focused on brand recognition, efficacy claims, pricing, and marketing. The nutraceuticals industry is a largely unregulated and fragmented industry. There are numerous companies that compete with us, and many of our competitors are larger than us, have greater access to capital, and may be better able to withstand volatile market conditions. Moreover, because the nutraceutical industry generally has low barriers to entry, additional competitors could enter the market at any time. In that regard, although the nutraceutical industry to date has been characterized by many relatively small participants, there can be no assurance that national or international companies (which may include pharmaceutical companies or other suppliers to mass merchandisers) will not seek to enter or to increase their presence in this industry. Increased competition in the industry could have an adverse effect on the Company.

 

According to Euromonitor International's report on Vitamins and Dietary Supplements in the US, dated April 2013 (copy on file with the Company), as of early 2013 there were six companies which controlled more than 2% each of the market, with the largest controlling 6%. Together this group controlled approximately 22.4% of the US market. According to the Euromonitor report, another 28 companies controlled approximately 24% of the market. This leaves approximately 53.6% of the market controlled by very small independent companies. The market is extremely competitive for similar products with over one hundred companies competing for market share.

 

DEPENDENCE ON FERRIS HOLDING

 

We rely on our majority shareholder, FHI, to a great extent for support. While we have incurred losses since inception, our business was funded initially by FHI and by majority shareholder and our Chairman of the Board, Barry Epling. If we cannot achieve commercial success in our products, we will need to continue to rely on FHI for support. If FHI at any time decides to alter or change materially our arrangement, we could experience a material adverse effect on the Company.

 

RELIANCE ON KEY MANAGEMENT

 

The operation of the Company requires managerial and operational expertise. In particular, the Company is dependent upon the management and leadership skills of Christopher G. Hall, our President, Chief Executive Officer, Chief Financial Officer, Secretary, and Barry Epling, the Chairman of the Board. Additionally, the Company relies heavily upon the professional medical and scientific advice from its Advisory Board which includes Dr. Jun Gu M.D., Ph.D., Dr. Edward E. Jacobs Jr. M.D., and Dr. Antonina Nabokova, M.D. None of the key management employees has a long-term employment contract with the Company, and there can be no assurance that such individuals will remain with the Company. The failure of such key personnel to continue to be active in management could have a material adverse effect on the Company.

 

 
12
 

  

RISKS ASSOCIATED WITH IMPLEMENTATION OF BUSINESS STRATEGY

 

Implementation of the Company's business strategy is subject to risks and uncertainties, including certain factors that are within the Company's control and other factors that are outside of the Company's control. In addition, certain elements of the Company's business strategy, notably the licensing of additional business lines from FHI, or other companies could result in significant expenditures of cash and management resources.

 

RISKS ASSOCIATED WITH ACQUISITIONS

 

The Company intends to use its equity to pursue acquisitions in the future as a component of the Company's business strategy, although as of the date of this Quarterly Report, the Company did not have any definitive agreements relating to any acquisitions. There can be no assurances that attractive acquisition opportunities will be available to the Company, that the Company will be able to obtain financing for or otherwise consummate any future acquisitions or that any acquisitions which are consummated will prove to be successful. Moreover, acquisitions involve numerous risks, including the risk that the acquired business will not perform in accordance with expectations, difficulties in the integration of the operations and products of the acquired businesses with the Company's other businesses, the diversion of management's attention from other aspects of the Company's business, the risks associated with entering geographic and product markets in which the Company has limited or no direct prior experience and the potential loss of key employees of the acquired business. The acquisition of another business can also subject the Company to liabilities and claims arising out of such business. In addition, future acquisitions would likely require additional financing, which would likely result in an increase in the Company's indebtedness or the issuance of additional capital stock which could be dilutive to holders of shares issued in the event of an Offering.

 

NO ASSURANCE OF FUTURE INDUSTRY GROWTH

 

Although market data referred to in this Quarterly Report and otherwise available to investors regarding the size and projected growth rates of the nutraceuticals market and our target demographic indicate that such markets are large and rapidly growing, there can be no assurance that such markets are as large as reported or that such projected growth will occur or continue. Market data and projections, such as those presented in this Quarterly Report, are inherently uncertain and subject to change. In addition, the underlying market conditions are subject to change based on economic conditions, consumer preferences and other factors that are beyond the Company's control. There can be no assurance that an adverse change in size or growth rate of the nutraceuticals market will not have a material adverse effect on the Company.

 

RISKS ASSOCIATED WITH INTERNATIONAL MARKETS

 

The Company's growth likely will be dependent in part upon its ability to expand its operations into new markets, including international markets. The Company may experience difficulty entering new international markets due to greater regulatory barriers, the necessity of adapting to new regulatory systems and problems related to entering new markets with different cultural bases and political systems. Operating in international markets exposes the Company to certain risks, including, among other things: (i) changes in or interpretations of foreign regulations that may limit the Company's ability to sell certain products or repatriate profits to the United States, (ii) exposure to currency fluctuations, (iii) the potential imposition of trade or foreign exchange restrictions or increased tariffs and (iv) political instability. If the Company seeks to expand international operations, these and other risks associated with international operations are likely to increase.

 

 
13
 

 

Recent Developments

 

Ferris Holding Licensing Agreement

 

On September 1, 2014, the Company entered into a License Agreement ("Agreement") with the Ferris Holding, Inc. ("FHI"), a related party. The Agreement gives the Company the right use of the Ferris's proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

Essence International Sub-License Agreement

 

On September 1, 2014, the Company entered into a Sub-License Agreement ("Sub-License") with Essence International, Ltd. ("Essence"), a related party. The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

Results of Operations for the three months ended June 30, 2016 and 2015

 

Through the periods ended June 30, 2016 and 2015, respectively, our operations continue to consist of primarily product research, development and testing. Sales are expected to commence in the third quarter of 2016, however there were no sales in the prior three months or in the same period in 2015. Our operation expenses in 2016 decreased, primarily due to a decrease in the market research and planning agreement we formed with Total Spectrum Advertising and professional fees. Our Net Loss decreased for the period primarily due to a decrease in operating expenses in 2016.

 

Our operating results are summarized as follows:

 

 

 

 Three Months Ended June 30,

 

 

 

 

 

 

2016

 

 

2015

 

 

Change

 

Revenue

 

$-

 

 

$-

 

 

 

-

 

Cost of sales

 

$-

 

 

$-

 

 

 

-

 

Operating expenses

 

$33,205

 

 

$109,357

 

 

 

(76,152)

Other income (expenses)

 

$-

 

 

$-

 

 

 

-

 

Net income (loss)

 

$(33,205)

 

$(109,357)

 

 

76,152

 

 

 
14
 

 

Revenues

 

The Company did not earn any revenues for the three months ended June 30, 2016 and 2015.

 

Operating Expenses

 

Our operating expenses are outlined in the table below:

 

 

 

 Three Months Ended June 30,

 

 

 

 

 

 

2016

 

 

2015

 

 

Change

 

General and administrative

 

$24,428

 

 

$95,725

 

 

 

(71,297)

Depreciation

 

 

132

 

 

 

132

 

 

 

-

 

Professional fees

 

 

8,645

 

 

 

13,500

 

 

 

(4,855)

Total

 

$33,205

 

 

$109,357

 

 

 

(76,152)

 

Our general, administrative and professional fees are largely attributable to office, rent, advertising and proportion fees, transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company.

 

Our general and administrative expenses decreased in the three months ended June 30, 2016 due to advertising and promotion fees. We continue to expense the stock-based compensation for our President, Christopher G. Hall. We have also reduced our dependence on outside professionals to support our accounting process, which has resulted in a decrease in Professional Fees, in the three months ended June 30, 2016, compared to the three months ended June 30, 2015.

 

Net loss

 

As a result of our operating expenses the Company reported a net loss of $33,205 and $109,357 for the three months ended June 30, 2016 and 2015, respectively.

 

Comprehensive income (loss)

 

The Company reported an unrealized loss on marketable securities of $2,707 and $16,283 for the three months ended June 30, 2016 and 2015, respectively.

 

Results of Operations for the six months ended June 30, 2016 and 2015

 

Through the periods ended June 30, 2016 and 2015, respectively, our operations continue to consist of primarily product research, development and testing. Sales are expected to commence in the third quarter of 2016, however there were no sales in the prior six months or in the same period in 2015. Our operation expenses in 2016 decreased, primarily due to professional fees. Our Net Loss decreased for the period primarily due to a decrease in operating expenses in 2016.

 

 
15
 

  

Our operating results are summarized as follows:

 

 

 

 Six Months Ended June 30,

 

 

 

 

 

 

2016

 

 

2015

 

 

Change

 

Revenue

 

$-

 

 

$-

 

 

 

-

 

Cost of sales

 

$-

 

 

$-

 

 

 

-

 

Operating expenses

 

$114,129

 

 

$138,627

 

 

 

(24,498)

Other income (expenses)

 

$-

 

 

$(156)

 

 

156

 

Net income (loss)

 

$(114,129)

 

$(138,783)

 

 

24,654

 

 

Revenues

 

The Company did not earn any revenues for the six months ended June 30, 2016 and 2015.

 

Operating Expenses

 

Our operating expenses are outlined in the table below:

 

 

 

 Six Months Ended June 30,

 

 

 

 

 

 

2016

 

 

2015

 

 

Change

 

General and administrative

 

$100,592

 

 

$108,332

 

 

 

(7,740)

Professional fees

 

 

13,274

 

 

 

30,031

 

 

 

(16,757)

Depreciation

 

 

263

 

 

 

264

 

 

 

(1)

Total

 

$114,129

 

 

$138,627

 

 

 

(24,498)

 

Our general, administrative and professional fees are largely attributable to office, rent, advertising and proportion fees, transfer agent, legal, accounting and audit fees related to our reporting requirements as a public company.

 

Our general and administrative expenses decreased in the six months ended June 30, 2016 due to advertising and promotion fees. We continue to expense the stock-based compensation for our President, Christopher G. Hall, which is a two-year employment agreement for services to be provided which will be instrumental in to the Company. We have also reduced our dependence on outside professionals to support our accounting process, which has resulted in a decrease in Professional Fees, in the six months ended June 30, 2016, compared to the six months ended June 30, 2015.

 

We anticipate that we will incur approximately $50,000 for operating expenses, including, legal, accounting and audit expenses associated with our reporting requirements as a public company under the Exchange Act during the next twelve months.

 

 
16
 

  

Other income (expense)

 

The Company recorded interest expense – related party of $0 and $156 for the six months ended June 30, 2016 and 2015, respectively.

 

Net loss

 

As a result of our operating expenses the Company reported a net loss of $114,129 and 138,783 for the six months ended June 30, 2016 and 2015, respectively.

 

Comprehensive income (loss)

 

The Company reported an unrealized loss on marketable securities of $2,009 and $19,561 for the six months ended June 30, 2016 and 2015, respectively.

 

Liquidity and Capital Resources

 

Working Capital (Deficiency)

 

 

 

June 30, 2016

 

 

December 31, 2015

 

 

Change

 

Current Assets

 

$149,057

 

 

$6,663

 

 

 

142,394

 

Current Liabilities

 

$296,993

 

 

$210,564

 

 

 

86,429

 

Working Capital (Deficiency)

 

$(147,936)

 

$(203,901)

 

 

55,965

 

 

Our working capital deficiency decreased as of June 30, 2016 as compared to December 31, 2015, primarily due to the purchase of inventory of $144,402 and a decrease in account payable of $24,709, offset by an increase in advance from Ferris Holding, related party of $102,138 and accrued liabilities of $9,000.

 

Cash Flows

 

 

 

 Six Months Ended June 30,

 

 

 

 

 

 

2016

 

 

2015

 

 

Change

 

Cash used in Operating Activities

 

$(1,922)

 

$(1,159)

 

 

(763)

Cash used in Investing Activities

 

$-

 

 

 

-

 

 

 

-

 

Cash provided by (used in) Financing Activities

 

$1,923

 

 

$(36,700)

 

 

38,623

 

Net Increase (Decrease) In Cash During Period

 

$1

 

 

$(37,859)

 

 

37,860

 

 

 
17
 

 

Cash used in Operating Activities

 

Our net loss for the six months ended June 30, 2016 of $114,129, was the main contributing factor for our negative operating cash flow, offset primarily by accounts payable that provided cash of $75,506 and stock based compensation that provided cash of $27,438.

 

For the six months ended June 30, 2015, our net loss of $138,783 was the main contributing factor for our negative operative cash flow, offset primarily by accounts payable – related party that provided cash of $115,650 and stock based compensation that provided cash of $21,710.

 

Cash provided by (used in) Financing Activities

 

Our net cash provided by financing activities for the six months ended June 30, 2016, was the result of advances from a related party of $4,873 and payment on advances from a related party of $2,950.

 

For the six months ended June 30, 2015, cash flows used in financing activities were the result of $2,700 paid on advances from a related party, and $34,000 paid on the principal of related party debt.

 

As of June 30, 2016, we have insufficient cash to operate our business at the current level for the next twelve months and insufficient cash to achieve our business goals. The success of our business plan beyond the next 12 months is contingent upon us obtaining additional financing. We intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our capital expenditures, working capital, or other cash requirements. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

 

Going Concern

 

At June 30, 2016, we had $100 of cash on-hand and an accumulated deficit of $2,935,273, and as noted throughout this report and our financial statements and notes thereto, our independent auditors have expressed their substantial doubt as to our ability to continue as a going concern as of June 30, 2016. We anticipate incurring significant losses in the future. We do not have an established source of revenue sufficient to cover our operating costs. Our ability to continue as a going concern is dependent upon our ability to successfully compete, operate profitably and/or raise additional capital through other means. If we are unable to reverse our losses, we will have to discontinue operations.

 

The financial statements included in this quarterly report have been prepared assuming that we will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business.

 

Management's plans include the raising of capital through the equity markets to fund future operations, seeking additional acquisitions, and generating of revenue through our business. However, even if we do raise sufficient capital to support our operating expenses and generate adequate revenues, there can be no assurances that the revenue will be sufficient to enable us to develop business to a level where we will generate profits and positive cash flows from operations. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amounts and classification of liabilities that might result from this uncertainty.

 

 
18
 

  

Off-Balance Sheet Arrangements

 

We did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

 

Critical Accounting Policies

 

Our financial statements are based on the application of accounting principles generally accepted in the United States ("US GAAP"). US GAAP requires the use of estimates; assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to US GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

 

Our significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies impact our financial condition and results of operations, we view certain of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause an effect on our results of operations, financial position or liquidity for the periods presented in this report.

 

Recently Issued Accounting Pronouncements

 

The Company has evaluated recent pronouncements through Accounting Standards Updates ("ASU") and believes that none of them will have a material impact on the Company's financial position, results of operations or cash flows.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

 

Not applicable.

 

Item 4. Controls and Procedures

 

Evaluation of Disclosure Controls and Procedures

 

As required by Rule 13a-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this quarterly report, June 30, 2016. This evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

 

 
19
 

  

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our company's reports filed under the Securities Exchange Act of 1934 is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

 

Based upon that evaluation, including our Chief Executive Officer and Chief Financial Officer, we have concluded that our disclosure controls and procedures were ineffective as of the end of the period covered by this report due to a material weakness in our internal control over financial reporting, which is described below.

 

Management's Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934). Management has assessed the effectiveness of our internal control over financial reporting as of June 30, 2016, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. As a result of this assessment, management concluded that, as of June 30, 2016, our internal control over financial reporting was not effective. Our management identified the following material weaknesses in our internal control over financial reporting, which are indicative of many small companies with small staff: (i) inadequate segregation of duties and effective risk assessment; and (ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both USGAAP and SEC guidelines.

 

We plan to take steps to enhance and improve the design of our internal control over financial reporting. During the period covered by this quarterly report on Form 10-Q, we have not been able to remediate the material weaknesses identified above. To remediate such weaknesses, we hope to implement the following changes during our fiscal year ending December 31, 2016: (i) appoint additional qualified personnel to address inadequate segregation of duties and ineffective risk management; and (ii) adopt sufficient written policies and procedures for accounting and financial reporting. The remediation efforts set out in (i) and (ii) are largely dependent upon our securing additional financing to cover the costs of implementing the changes required. If we are unsuccessful in securing such funds, remediation efforts may be adversely affected in a material manner.

 

Changes in Internal Control over Financial Reporting

 

There was no change in the Company's internal control over financial reporting that occurred during the Company's most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

 

 
20
 

  

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

We know of no pending legal proceedings to which we are a party which are material or potentially material, either individually or in the aggregate. We are from time to time, during the normal course of our business operations, subject to various litigation claims and legal disputes. We do not believe that the ultimate disposition of any of these matters will have a material adverse effect on our consolidated financial position, results of operations or liquidity.

 

Item 1A. Risk Factors

 

A smaller reporting company is not required to provide the information required by this Item.

 

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

 

None

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

Not applicable.

 

Item 5. Other Information

 

None.

 

 
21
 

  

Item 6. Exhibits

 

(a) Exhibits

 

Exhibit
Number

Description

3.1

Certificate of Incorporation (1)

3.2

Bylaws (1)

4.1

Specimen Stock Certificate (1)

31.1

Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2

Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101

The following materials from the Company's Annual Report on Form 10-K for the year ended December 31, 2015 formatted in Extensible Business Reporting Language (XBRL).

_________________

(1)

Incorporated by reference to Current Report on Form 10 filed on May 3, 2013

 

 
22
 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

    
Date: August 18, 2016By:/s/ Christopher G. Hall

 

 

Christopher G. Hall 
  President, Chief Executive Officer, Chief Financial Officer, Secretary 
  (Principal Executive Officer, Principal Financial Officer) 

 

    
Date: August 18, 2016By:/s/ Barry Epling

 

 

Barry Epling 
  Chairman of the Board of Directors 
    

 

 

23

 

 

 

EX-31.1 2 bioadaptives_ex311.htm CERTIFICATION bioadaptives_ex311.htm

EXHIBIT 31.1

 

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

 

I, Christopher G. Hall, certify that:

 

1.I have reviewed this Form 10-Q of BioAdaptives Inc.;

 

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

 

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Dated: August 18, 2016

By:

/s/ Christopher G. Hall

Christopher G. Hall

Chief Executive Officer

(Principal Executive Officer)

 

EX-31.2 3 bioadaptives_ex312.htm CERTIFICATION bioadaptives_ex312.htm

EXHIBIT 31.2

 

BIOADAPTIVES INC.

OFFICER'S CERTIFICATE PURSUANT TO SECTION 302

 

I, Christopher G. Hall, certify that:

 

1.I have reviewed this Form 10-Q of BioAdaptives Inc.;

 

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

 

4.The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

 

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

 

 

c.Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

 

 

d.Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5.The registrant's other certifying officer(s) and I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

 

 

 

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

 

Dated: August 18, 2016

By:

/s/ Christopher G. Hall

Christopher G. Hall

Chief Financial Officer

(Principal Financial Officer)

 

EX-32.1 4 bioadaptives_ex321.htm CERTIFICATION bioadaptives_ex321.htm

EXHIBIT 32.1

 

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Christopher G. Hall, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

 

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Christopher G. Hall and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

Dated: August 18, 2016

By:

/s/ Christopher G. Hall

Christopher G. Hall

Chief Executive Officer

(Principal Executive Officer)

 

EX-32.2 5 bioadaptives_ex322.htm CERTIFICATION bioadaptives_ex322.htm

EXHIBIT 32.2

 

BIOADAPTIVES INC.

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 906 OF

THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of BioAdaptives Inc. (the Registrant) on Form 10-Q for the period ended June 30, 2016 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Christopher G. Hall, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 

 

 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

A signed original of this written statement required by Section 906 has been provided to Christopher G. Hall and will be retained by BioAdaptives Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

Dated: August 18, 2016

By:

/s/ Christopher G. Hall

Christopher G. Hall

Chief Financial Officer

(Principal Accounting Officer)

 

EX-101.INS 6 bdpt-20160630.xml XBRL INSTANCE DOCUMENT 0001575142 us-gaap:SubsidiariesMember 2013-09-11 0001575142 us-gaap:MajorityShareholderMember 2014-05-01 2014-06-01 0001575142 us-gaap:MajorityShareholderMember 2014-08-31 2014-09-01 0001575142 bdpt:EssenceInternationalLtdMember bdpt:SubLicenseAgreementMember 2014-08-31 2014-09-01 0001575142 us-gaap:ChiefExecutiveOfficerMember 2015-02-06 0001575142 us-gaap:ChiefExecutiveOfficerMember 2015-02-01 2015-02-06 0001575142 2015-04-01 2015-06-30 0001575142 2015-01-01 2015-06-30 0001575142 2015-12-31 0001575142 us-gaap:MajorityShareholderMember 2015-12-31 0001575142 us-gaap:MajorityShareholderMember 2016-02-15 0001575142 us-gaap:MajorityShareholderMember 2016-02-01 2016-02-15 0001575142 2016-04-01 2016-06-30 0001575142 2016-01-01 2016-06-30 0001575142 us-gaap:MajorityShareholderMember 2016-01-01 2016-06-30 0001575142 2016-06-30 0001575142 us-gaap:MajorityShareholderMember 2016-06-30 0001575142 us-gaap:FairValueInputsLevel1Member 2016-06-30 0001575142 us-gaap:FairValueInputsLevel2Member 2016-06-30 0001575142 us-gaap:FairValueInputsLevel3Member 2016-06-30 0001575142 us-gaap:CommonStockMember bdpt:HempIncMember 2016-06-30 0001575142 us-gaap:MajorityShareholderMember us-gaap:SubsequentEventMember 2016-08-01 2016-08-11 0001575142 2016-08-18 0001575142 2014-12-31 0001575142 2015-06-30 xbrli:shares iso4217:USD iso4217:USDxbrli:shares xbrli:pure BIOADAPTIVES, INC. 0001575142 bdpt --12-31 Smaller Reporting Company 14180456 10-Q 2016-06-30 false 2016 Q2 99 100 37871 12 144402 1700 1700 4864 2855 2855 2855 6663 149057 527 264 7190 149321 34354 9645 25361 25361 34361 34361 150849 150849 252987 252987 210564 296993 210564 296993 1275 1419 2673170 2844866 -56675 -58684 -2821144 -2935273 -203374 -147672 7190 149321 0.0001 0.0001 5000000 5000000 0 0 0 0 0.0001 0.0001 100000000 100000000 12736436 14180456 12736436 14180456 132 264 132 263 95725 108332 24428 100592 13500 30031 8645 13274 109357 138627 33205 114129 -109357 -138627 -33205 -114129 156 -156 -109357 -138783 -33205 -114129 -16283 -19561 -2707 -2009 -16283 -19561 -2707 -2009 -125640 -158344 -35912 -116138 -0.01 -0.01 -0.00 -0.01 12654214 12654214 14180456 13823350 21710 27438 75506 115650 9000 -1159 -1922 4873 4873 -2700 -2950 34000 2950 -36700 1923 -37859 1 902 100215 100215 19561 2009 144402 <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>1.&#160;<u>DESCRIPTION OF BUSINESS AND HISTORY</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Description of business</u>&#160;&#8211; BioAdaptives, Inc. (formerly known as APEX 8 Inc.) ("BioAdaptives", "Company") was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc ("Blenders") in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On September 1, 2014, the Company entered into a License Agreement ("Agreement") with Ferris Holding, Inc. ("Ferris"). The Agreement gives the Company the right to use Ferris's proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On September 1, 2014, the Company entered into a Sub-License Agreement ("Sub-License") with Essence International, Ltd. ("Essence"). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Basis of presentation</u>&#160;&#8211; The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>2.&#160;<u>SUMMARY OF SIGNIFICANT POLICIES</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Investment Securities</u>&#160;- Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Fair value of financial instruments&#160;</u>&#8211; As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 1</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p> </td> </tr> <tr> <td valign="top" width="11%"></td> <td valign="top" width="88%"></td> </tr> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 2</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</p> </td> </tr> <tr> <td valign="top" width="11%"></td> <td valign="top" width="88%"></td> </tr> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 3</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</p> </td> </tr> </table> <p>&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of June 30, 2016.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p align="center" style="margin: 0px; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>Fair Value Measurements as of June 30, 2016 Using:</b></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table align="center" style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><strong>Total Carrying Value </strong><strong>as of</strong></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Quoted Market Prices in Active Markets</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Other Observable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Unobservable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>June 30, 2016</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 1)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 2)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 3)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="top"> <p style="margin: 0px; text-indent: 0px;"><b>Assets:</b></p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Equity Securities</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Total</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p>&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Equity securities at June 30, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $2,855 ($0.027 per share).</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Inventory</u></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at June 30, 2016, the Company determined that no reserve was required.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The inventory acquired during the period has been accounted for at consideration, which was based on the shares provided in the transaction to an entity under common control. Total consideration for the $144,402 of inventory resulted in the issuance of 1,444,020 common shares based on the value of $0.10 per share at the transaction date.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>3.<u>&#160;GOING CONCERN</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $2,935,273 as of June 30, 2016. The Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>4.&#160;<u>STOCKHOLDERS' EQUITY</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Preferred Stock</u>&#160;&#8211; The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of June 30, 2016 and December 31, 2015, no shares of preferred stock had been issued.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Common Stock</u>&#160;&#8211; The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock. As of June 30, 2016 and December 31, 2015, there were 14,180,456 and 12,736,436 shares of the Company's common stock issued and outstanding, respectively.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On February 15, 2016, the Company issued 1,444,020 shares of common stock to Ferris Holding, Inc. a common control entity for the purchase of inventory valued at $144,402.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two years of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, $1.10 per share, which resulted in a total consideration of $110,050 which will be expensed throughout the two-year term of the employment agreement. For the six months ended June 30, 2016 and 2015, the Company expensed $27,438 and $21,710, respectively.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>5.&#160;<u>RELATED PARTY TRANSACTIONS</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Advances from Ferris Holding, Inc., the controlling shareholder of the Company, are non-interest bearing, unsecured and due on demand. During the six months ended June 30, 2016, $100,215 was paid by Ferris Holding, Inc. on behalf of the Company and the Company received cash advance of $4,873 from Ferris Holding, Inc and repaid $2,950 to Ferris Holding. As of June 30, 2016 and December 31, 2015, the Company had advances from Ferris Holdings, Inc. &#8211; related party balance of $252,987 and $150,849, respectively.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On February 15, 2016, the sole member of the Board of directors of BioAdaptives adopted the following resolution and the President was authorized to negotiate the purchase of the below referenced products from Ferris Holding, Inc., an entity under common control and to pay for the products with the Company's common stock.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td width="2%"></td> <td valign="top" width="4%"> <p style="margin: 0px; text-indent: 0px;"><font style="font-family: symbol;">&#183;</font></p> </td> <td valign="top" width="92%"> <p style="margin: 0px; text-indent: 0px;">Ferris Holding Inc. has manufactured the following products for the Company: PrimiCell<font style="font-family: symbol;">&#210;</font>, PrimiLive<font style="font-family: symbol;">&#210;</font>, PrimiTrimTM and Equine Regen<font style="font-family: symbol;">&#210;</font>Plus; and</p> </td> </tr> </table> <p>&#160;</p> <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td width="2%"></td> <td valign="top" width="4%"> <p style="margin: 0px; text-indent: 0px;"><font style="font-family: symbol;">&#183;</font></p> </td> <td valign="top" width="92%"> <p style="margin: 0px; text-indent: 0px;">The Company chooses to purchase the products for distribution by the Company</p> </td> </tr> </table> <p>&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On February 15, 2016, the Company purchased inventory for $144,402 from Ferris Holding, Inc.,&#160;the controlling shareholder of the Company. In accordance with ASC 805, the transaction is considered to be a transfer of assets under common control. The consideration for the inventory was the issuance of 1,444,020 of common shares at the rate of $0.10 per share on the date of the transaction. On August 11, 2016, the Company physically issued 1,444,020 shares of common stock.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On February 6, 2015, the Company entered into a two (2) year employment agreement with its chief executive officer, Christopher G. Hall, whereby the Company issued 100,000 shares of restricted common stock as compensation for two (2) years of executive services to be performed. The shares were valued at the closing share price of $1.10 on the date of the agreement. This resulted in compensation expense of $110,050 being amortized over the two (2) year term of the employment agreement. Compensation expense of $27,438 was amortized for six months ended June 30, 2016.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is $1,500. The term of the lease is month to month. As of June 30, 2016 and December 31, 2015, the Company has a rent payable due to Ferris in the amount of $34,361 and $25,361, respectively, which is included in our accrued liabilities &#8211; related party balance in our consolidated balance sheets.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Investment Securities</u>&#160;- Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Fair value of financial instruments&#160;</u>&#8211; As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 1</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</p> </td> </tr> <tr> <td valign="top" width="11%"></td> <td valign="top" width="88%"></td> </tr> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 2</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;</p> </td> </tr> <tr> <td valign="top" width="11%"></td> <td valign="top" width="88%"></td> </tr> <tr> <td valign="top" width="11%"> <p style="margin: 0px; text-indent: 0px;">Level 3</p> </td> <td valign="top" width="88%"> <p style="margin: 0px; text-indent: 0px;">Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).</p> </td> </tr> </table> <p></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of June 30, 2016.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p align="center" style="margin: 0px; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><b>Fair Value Measurements as of June 30, 2016 Using:</b></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <table style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><strong>Total Carrying Value&#160;</strong><strong>as of</strong></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Quoted Market Prices in Active Markets</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Other Observable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Unobservable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>June 30, 2016</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 1)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 2)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 3)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="top"> <p style="margin: 0px; text-indent: 0px;"><b>Assets:</b></p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Equity Securities</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Total</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> <p></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Equity securities at June 30, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $2,855 ($0.027 per share).</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><u>Inventory</u></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at June 30, 2016, the Company determined that no reserve was required.</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">The inventory acquired during the period has been accounted for at consideration, which was based on the shares provided in the transaction to an entity under common control. Total consideration for the $144,402 of inventory resulted in the issuance of 1,444,020 common shares based on the value of $0.10 per share at the transaction date.</p> <table align="center" style="font: 10pt/normal 'times new roman'; width: 100%; text-align: justify; font-size-adjust: none; font-stretch: normal;" border="0" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><strong>Total Carrying Value </strong><strong>as of</strong></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Quoted Market Prices in Active Markets</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Other Observable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" valign="bottom" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>Significant Unobservable Inputs</b></p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>June 30, 2016</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 1)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 2)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> <td align="center" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%" colspan="2"> <p align="center" style="margin: 0px; text-indent: 0px;"><b>(Level 3)</b></p> </td> <td style="padding-bottom: 1px;" valign="bottom"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr> <td valign="top"> <p style="margin: 0px; text-indent: 0px;"><b>Assets:</b></p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td align="right" valign="bottom" width="9%" colspan="2"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#cceeff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Equity Securities</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> <tr bgcolor="#ffffff"> <td valign="top"> <p style="margin: 0px; text-indent: 0px;">Total</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">2,855</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> <td style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="1%">$</td> <td align="right" style="border-bottom-color: currentcolor; border-bottom-width: 1px; border-bottom-style: solid;" valign="bottom" width="9%">-</td> <td style="padding-bottom: 1px;" valign="bottom" width="1%"> <p style="margin: 0px;">&#160;</p> </td> </tr> </table> 1.00 the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. 2855 2855 105736 0.027 144402 1444020 1444020 0.10 100000 P2Y 1.10 110050 P2Y 1500 <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;"><strong>6.&#160;<u>SUBSEQUENT EVENT</u></strong></p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">&#160;</p> <p style="margin: 0px; text-align: justify; color: #000000; text-transform: none; line-height: normal; text-indent: 0px; letter-spacing: normal; font-family: 'times new roman'; font-size: 13.33px; font-style: normal; font-weight: normal; word-spacing: 0px; white-space: normal; orphans: 2; widows: 2; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px;">On August 11, 2016, the Company physically issued 1,444,020 shares of common stock to Ferris Holding, Inc. for the purchase of inventory valued at $144,402.</p> 110050 P2Y 144402 EX-101.SCH 7 bdpt-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - SUBSEQUENT EVENT link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables) link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details) link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details Textual) link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - GOING CONCERN (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - STOCKHOLDERS'EQUITY (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - SUBSEQUENT EVENT (Details) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 bdpt-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bdpt-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bdpt-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 bdpt-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 bioadaptives_10qimg1.jpg begin 644 bioadaptives_10qimg1.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2016
Aug. 18, 2016
Document and Entity Information [Abstract]    
Entity Registrant Name BIOADAPTIVES, INC.  
Entity Central Index Key 0001575142  
Trading Symbol bdpt  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Entity Common Stock, Shares Outstanding   14,180,456
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Amendment Flag false  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Current Assets:    
Cash $ 100 $ 99
Inventory 144,402  
Deposit 1,700 1,700
Marketable securities 2,855 4,864
Total Current Assets 149,057 6,663
Furniture and Fixtures, net 264 527
TOTAL ASSETS 149,321 7,190
Current Liabilities:    
Accounts payable 9,645 34,354
Accrued liabilities - related party 34,361 25,361
Advance from Ferris Holding, Inc. - related party 252,987 150,849
Total Current Liabilities 296,993 210,564
Total Liabilities 296,993 210,564
Stockholders' Deficit:    
Preferred stock, ($.0001 par value, 5,000,000 shares authorized; none issued and outstanding.)
Common stock ($.0001 par value, 100,000,000 shares authorized; 14,180,456 and 12,736,436 shares issued and outstanding as of June 30, 2016 and December 31, 2015, respectively) 1,419 1,275
Additional paid-in capital 2,844,866 2,673,170
Accumulated other comprehensive income (loss) (58,684) (56,675)
Accumulated deficit (2,935,273) (2,821,144)
Total Stockholders' Deficit (147,672) (203,374)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 149,321 $ 7,190
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Consolidated Balance Sheets [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 14,180,456 12,736,436
Common stock, shares outstanding 14,180,456 12,736,436
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Income Statement [Abstract]        
Revenues
Cost of revenue
Gross Margin
Operating Expenses        
Depreciation 132 132 263 264
General and administrative 24,428 95,725 100,592 108,332
Professional fees 8,645 13,500 13,274 30,031
Total Operating Expenses 33,205 109,357 114,129 138,627
Operating Income (Loss) (33,205) (109,357) (114,129) (138,627)
Other Income (Expense)        
Interest - related party       (156)
Total Other Income (Expense)       (156)
Net Loss (33,205) (109,357) (114,129) (138,783)
Other Comprehensive Income (Loss), net of tax        
Unrealized gain (loss) on marketable securities (2,707) (16,283) (2,009) (19,561)
Other Comprehensive Income (Loss) (2,707) (16,283) (2,009) (19,561)
Comprehensive Income (Loss) $ (35,912) $ (125,640) $ (116,138) $ (158,344)
Net Loss Per Share: Basic and Diluted (in dollars per share) $ (0.00) $ (0.01) $ (0.01) $ (0.01)
Weighted Average Number of Shares Outstanding: Basic and Diluted (in shares) 14,180,456 12,654,214 13,823,350 12,654,214
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
CASH FLOWS FROM OPERATING ACTIVITIES    
Net loss $ (114,129) $ (138,783)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation 263 264
Stock-based compensation - related party 27,438 21,710
Changes in operating assets and liabilities:    
Accounts payable 75,506  
Accrued liabilities - related party 9,000 115,650
Net Cash Used In Operating Activities (1,922) (1,159)
CASH FLOWS FROM FINANCING ACTIVITIES    
Advances from related party 4,873  
Payment on advances from related party (2,950) (2,700)
Principal payments on related party debt   (34,000)
Net Cash Provided By (Used In) Financing Activities 1,923 (36,700)
Net change in cash 1 (37,859)
Cash at beginning of period 99 37,871
Cash at end of period 100 12
SUPPLEMENTAL CASH FLOW INFORMATION:    
Cash paid for income taxes
Cash paid for interest   902
NON CASH INVESTING AND FINANCING ACTIVITIES    
Settlement of liabilities by related party 100,215  
Unrealized loss on investments in marketable securities 2,009 $ 19,561
Purchase of inventory by common shares $ 144,402  
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
DESCRIPTION OF BUSINESS AND HISTORY
6 Months Ended
Jun. 30, 2016
Description of Business and History and Basis of Presentation [Abstract]  
DESCRIPTION OF BUSINESS AND HISTORY AND BASIS OF PRESENTATION

1. DESCRIPTION OF BUSINESS AND HISTORY

 

Description of business – BioAdaptives, Inc. (formerly known as APEX 8 Inc.) ("BioAdaptives", "Company") was incorporated under the laws of the State of Delaware on April 19, 2013. BioAdaptives is a research, development, and educational company. Our current focus is on products that improve health and wellness. These products include dietary supplements, specialty food items, and proprietary methods of optimizing the bioelectromagnetic availability of foods and beverages.

 

On September 11, 2013, BioAdaptives incorporated Blenders Choice Inc ("Blenders") in Nevada. Blenders is a 100% owned subsidiary and was created as a separate sales and marketing organization. BioAdaptives has elected to manage its sales through independent distributors and has suspended operations of Blenders Choice.

 

On September 1, 2014, the Company entered into a License Agreement ("Agreement") with Ferris Holding, Inc. ("Ferris"). The Agreement gives the Company the right to use Ferris's proprietary processes and trade secrets, including its stem cell enhancement products. In consideration for these rights, the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

On September 1, 2014, the Company entered into a Sub-License Agreement ("Sub-License") with Essence International, Ltd. ("Essence"). The Sub-License gives Essence the right to use proprietary processes and trade secrets, including its stem cell enhancement products which were obtained by the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months. The agreement is still current and an extension of the agreement has been verbally agreed upon by both parties.

 

Basis of presentation – The accompanying unaudited interim financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission, and should be read in conjunction with the audited financial statements and notes thereto contained in the Company's most recent Annual Financial Statements filed with the SEC on Form 10-K. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations for the interim period are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements which would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal period, as reported in the Form 10-K, have been omitted.

XML 19 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT POLICIES
6 Months Ended
Jun. 30, 2016
Summary of Significant Policies [Abstract]  
SUMMARY OF SIGNIFICANT POLICIES

2. SUMMARY OF SIGNIFICANT POLICIES

 

Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

 

In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

 

Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

 

Level 1

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2

Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

 

Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of June 30, 2016.

 

Fair Value Measurements as of June 30, 2016 Using:

 

 

 

Total Carrying Value as of

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

June 30, 2016

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Equity Securities

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

Total

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

 

Equity securities at June 30, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $2,855 ($0.027 per share).

 

 

Inventory

 

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at June 30, 2016, the Company determined that no reserve was required.

 

The inventory acquired during the period has been accounted for at consideration, which was based on the shares provided in the transaction to an entity under common control. Total consideration for the $144,402 of inventory resulted in the issuance of 1,444,020 common shares based on the value of $0.10 per share at the transaction date.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
GOING CONCERN
6 Months Ended
Jun. 30, 2016
Going Concern [Abstract]  
GOING CONCERN

3. GOING CONCERN

 

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $2,935,273 as of June 30, 2016. The Company requires capital for its contemplated operational and marketing activities. The Company's ability to raise additional capital through the future issuances of common stock is unknown. The obtainment of additional financing, the successful development of the Company's contemplated plan of operations, and its transition, ultimately, to the attainment of profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raise substantial doubt about the Company's ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

 

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2016
Stockholders' Equity [Abstract]  
STOCKHOLDERS' EQUITY

4. STOCKHOLDERS' EQUITY

 

Preferred Stock – The Company is authorized to issue 5,000,000 shares of $.0001 par value preferred stock. As of June 30, 2016 and December 31, 2015, no shares of preferred stock had been issued.

 

Common Stock – The Company is authorized to issue 100,000,000 shares of $.0001 par value common stock. As of June 30, 2016 and December 31, 2015, there were 14,180,456 and 12,736,436 shares of the Company's common stock issued and outstanding, respectively.

 

On February 15, 2016, the Company issued 1,444,020 shares of common stock to Ferris Holding, Inc. a common control entity for the purchase of inventory valued at $144,402.

 

In the year ended December 31, 2015, the Company issued 100,000 shares of common stock to its chief executive officer, Christopher G. Hall, as compensation for two years of services to be performed pursuant to an employment agreement dated February 6, 2015. The Company valued the 100,000 shares of common stock on the date of the agreement, $1.10 per share, which resulted in a total consideration of $110,050 which will be expensed throughout the two-year term of the employment agreement. For the six months ended June 30, 2016 and 2015, the Company expensed $27,438 and $21,710, respectively.

XML 22 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2016
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

5. RELATED PARTY TRANSACTIONS

 

Advances from Ferris Holding, Inc., the controlling shareholder of the Company, are non-interest bearing, unsecured and due on demand. During the six months ended June 30, 2016, $100,215 was paid by Ferris Holding, Inc. on behalf of the Company and the Company received cash advance of $4,873 from Ferris Holding, Inc and repaid $2,950 to Ferris Holding. As of June 30, 2016 and December 31, 2015, the Company had advances from Ferris Holdings, Inc. – related party balance of $252,987 and $150,849, respectively.

 

On February 15, 2016, the sole member of the Board of directors of BioAdaptives adopted the following resolution and the President was authorized to negotiate the purchase of the below referenced products from Ferris Holding, Inc., an entity under common control and to pay for the products with the Company's common stock.

 

·

Ferris Holding Inc. has manufactured the following products for the Company: PrimiCellÒ, PrimiLiveÒ, PrimiTrimTM and Equine RegenÒPlus; and

 

·

The Company chooses to purchase the products for distribution by the Company

 

On February 15, 2016, the Company purchased inventory for $144,402 from Ferris Holding, Inc., the controlling shareholder of the Company. In accordance with ASC 805, the transaction is considered to be a transfer of assets under common control. The consideration for the inventory was the issuance of 1,444,020 of common shares at the rate of $0.10 per share on the date of the transaction. On August 11, 2016, the Company physically issued 1,444,020 shares of common stock.

 

On February 6, 2015, the Company entered into a two (2) year employment agreement with its chief executive officer, Christopher G. Hall, whereby the Company issued 100,000 shares of restricted common stock as compensation for two (2) years of executive services to be performed. The shares were valued at the closing share price of $1.10 on the date of the agreement. This resulted in compensation expense of $110,050 being amortized over the two (2) year term of the employment agreement. Compensation expense of $27,438 was amortized for six months ended June 30, 2016.

 

On June 1, 2014, the Company entered into a rental agreement with Ferris for the corporate office. Monthly rent is $1,500. The term of the lease is month to month. As of June 30, 2016 and December 31, 2015, the Company has a rent payable due to Ferris in the amount of $34,361 and $25,361, respectively, which is included in our accrued liabilities – related party balance in our consolidated balance sheets.

XML 23 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENT
6 Months Ended
Jun. 30, 2016
Subsequent Events [Abstract]  
SUBSEQUENT EVENT

6. SUBSEQUENT EVENT

 

On August 11, 2016, the Company physically issued 1,444,020 shares of common stock to Ferris Holding, Inc. for the purchase of inventory valued at $144,402.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT POLICIES (Policies)
6 Months Ended
Jun. 30, 2016
Summary of Significant Policies [Abstract]  
Investment Securities

Investment Securities - Equity securities are classified as available for sale and are stated at fair value with unrealized gains and losses excluded from earnings and reported in other comprehensive income, net of tax. All available for sale securities are classified as current assets as they are available to support the Company's current operating needs in the next 12 months. Realized gains and losses on the sale of investment securities are recognized at the settlement date using the specific identification method and are included in the statements of operations.

 

In accordance with Accounting Standards Codification ("ASC") 320-10, "Investments-Debt and Equity Securities," the Company evaluates its securities portfolio for other-than-temporary impairment ("OTTI") throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or in combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

Fair Value of Financial Instruments

Fair value of financial instruments – As required by the Fair Value Measurements and Disclosures Topic of FASB ASC 820-10 ("ASC 820-10"), fair value is measured based on a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: (Level 1) observable inputs such as quoted prices in active markets; (Level 2) inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and (Level 3) unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.. The three levels of the fair value hierarchy are as follows:

 

Level 1

Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2

Quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3

Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).

 

Pursuant to ASC 825, Financial Instruments, the fair value of cash, marketable securities and stock based compensation is determined based on "Level 1" inputs, which consist of quoted prices in active markets for identical assets. The Company believes that the recorded values of cash, accounts receivables, accounts payable and accrued liabilities, and notes payable approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

 

Assets measured at fair value on a recurring basis were presented on the Company's balance sheet as of June 30, 2016.

 

Fair Value Measurements as of June 30, 2016 Using:

 

 

 

Total Carrying Value as of

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

June 30, 2016

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Equity Securities

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

Total

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

 

Equity securities at June 30, 2016, were comprised of 105,736 shares of common stock of Hemp, Inc. (HEMP.PK) recorded at fair value of $2,855 ($0.027 per share).

Inventory

Inventory

 

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out ("FIFO") method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As at June 30, 2016, the Company determined that no reserve was required.

 

The inventory acquired during the period has been accounted for at consideration, which was based on the shares provided in the transaction to an entity under common control. Total consideration for the $144,402 of inventory resulted in the issuance of 1,444,020 common shares based on the value of $0.10 per share at the transaction date.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT POLICIES (Tables)
6 Months Ended
Jun. 30, 2016
Summary of Significant Policies [Abstract]  
Schedule of Fair Value of Measurements of Assets on Recurring Basis

 

 

Total Carrying Value as of

 

 

Quoted Market Prices in Active Markets

 

 

Significant Other Observable Inputs

 

 

Significant Unobservable Inputs

 

 

 

June 30, 2016

 

 

(Level 1)

 

 

(Level 2)

 

 

(Level 3)

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

Equity Securities

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

Total

 

$ 2,855

 

 

$ 2,855

 

 

$ -

 

 

$ -

 

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
DESCRIPTION OF BUSINESS AND HISTORY (Detail Textuals)
Sep. 01, 2014
Sep. 11, 2013
Blenders    
Description of Business and History and Basis of Presentation (Textual)    
Ownership Percentage   100.00%
Ferris Holding, Inc.    
Description of Business and History and Basis of Presentation (Textual)    
Agreement terms the Company agrees to pay Ferris a fee of 5% of the gross revenue for the products produced and sold by the Company or by way of sub-license pursuant to the rights granted under this Agreement. The initial term of the Agreement was twelve (12) months.  
Essence International, Ltd | Sub-License Agreement    
Description of Business and History and Basis of Presentation (Textual)    
Agreement terms the Company in the Agreement with Ferris. In consideration for the Sub-License, Essence agreed to pay the Company a royalty of 10% of the gross revenue for the products produced and sold by Essence pursuant to the rights granted under this Sub-License. The initial term of the Agreement was twelve (12) months.  
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT POLICIES (Details) - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Assets:    
Equity Securities $ 2,855 $ 4,864
Total 2,855  
Quoted Market Prices in Active Markets (Level 1)    
Assets:    
Equity Securities 2,855  
Total 2,855  
Significant Other Observable Inputs (Level 2)    
Assets:    
Equity Securities  
Total  
Significant Unobservable Inputs (Level 3)    
Assets:    
Equity Securities  
Total  
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUMMARY OF SIGNIFICANT POLICIES (Details Textual) - USD ($)
1 Months Ended
Feb. 15, 2016
Jun. 30, 2016
Dec. 31, 2015
Fair Value Inputs, Assets, Quantitative Information [Line Items]      
Marketable securities   $ 2,855 $ 4,864
Ferris Holding, Inc.      
Fair Value Inputs, Assets, Quantitative Information [Line Items]      
Value of shares issued $ 144,402    
Number of shares issued 1,444,020    
Share price $ 0.10    
Hemp, Inc | Common stock      
Fair Value Inputs, Assets, Quantitative Information [Line Items]      
Equity securities held   105,736  
Marketable securities   $ 2,855  
Equity securities of Hemp, Inc. fair value per share   $ 0.027  
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
GOING CONCERN (Detail Textuals) - USD ($)
Jun. 30, 2016
Dec. 31, 2015
Going Concern [Abstract]    
Accumulated deficit $ (2,935,273) $ (2,821,144)
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
STOCKHOLDERS'EQUITY (Detail Textuals) - USD ($)
1 Months Ended 6 Months Ended
Feb. 06, 2015
Feb. 15, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Preferred stock, shares authorized     5,000,000   5,000,000
Preferred stock, par value (in dollars per share)     $ 0.0001   $ 0.0001
Preferred stock, shares issued     0   0
Common stock, shares authorized     100,000,000   100,000,000
Common stock, par value (in dollars per share)     $ 0.0001   $ 0.0001
Common stock, shares issued     14,180,456   12,736,436
Common stock, shares outstanding     14,180,456   12,736,436
Stock-based compensation - related party     $ 27,438 $ 21,710  
Christopher G. Hall          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Stock issued for share based compensation, shares 100,000        
Service term 2 years        
Share price $ 1.10        
Stock issued for share based compensation, value $ 110,050        
Employment agreement term 2 years        
Ferris Holding, Inc.          
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]          
Number of shares issued   1,444,020      
Value of shares issued   $ 144,402      
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)
1 Months Ended 6 Months Ended
Aug. 11, 2016
Feb. 06, 2015
Feb. 15, 2016
Jun. 01, 2014
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Related Party Transaction [Line Items]              
Expenses paid         $ 100,215    
Advances from related party         4,873    
Repayment of advances           $ 34,000  
Advance from Ferris Holding, Inc. - related party         252,987   $ 150,849
Stock-based compensation - related party         27,438 $ 21,710  
Rent payable due to Ferris         34,361   25,361
Christopher G. Hall              
Related Party Transaction [Line Items]              
Employment agreement term   2 years          
Restricted common stock shares issued as compensation   100,000          
Service term   2 years          
Share price   $ 1.10          
Compensation expense to be recognized   $ 110,050          
Compensation expense recognition period (in years)   2 years          
Ferris Holding, Inc.              
Related Party Transaction [Line Items]              
Expenses paid         100,215    
Advances from related party         4,873    
Repayment of advances         2,950    
Advance from Ferris Holding, Inc. - related party         252,987   150,849
Value of shares issued     $ 144,402        
Number of shares issued     1,444,020        
Share price     $ 0.10        
Rent payable per month to Ferris       $ 1,500      
Rent payable due to Ferris         $ 34,361   $ 25,361
Ferris Holding, Inc. | Subsequent event              
Related Party Transaction [Line Items]              
Value of shares issued $ 144,402            
Number of shares issued 1,444,020            
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
SUBSEQUENT EVENT (Details) - Ferris Holding, Inc. - USD ($)
1 Months Ended
Aug. 11, 2016
Feb. 15, 2016
Subsequent Event [Line Items]    
Inventory purchase value   $ 144,402
Number of shares issued   1,444,020
Subsequent event    
Subsequent Event [Line Items]    
Inventory purchase value $ 144,402  
Number of shares issued 1,444,020  
EXCEL 33 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end
XML 34 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 35 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 37 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 25 94 1 false 11 0 false 4 false false R1.htm 001 - Document - Document and Entity Information Sheet http://bioadaptives.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 002 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://bioadaptives.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://bioadaptives.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Sheet http://bioadaptives.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveIncomeLoss CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) Statements 4 false false R5.htm 005 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://bioadaptives.com/role/ConsolidatedStatementsOfCashFlowsUnaudited CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) Statements 5 false false R6.htm 006 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY Sheet http://bioadaptives.com/role/DescriptionOfBusinessAndHistory DESCRIPTION OF BUSINESS AND HISTORY Notes 6 false false R7.htm 007 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES Sheet http://bioadaptives.com/role/SummaryOfSignificantPolicies SUMMARY OF SIGNIFICANT POLICIES Notes 7 false false R8.htm 008 - Disclosure - GOING CONCERN Sheet http://bioadaptives.com/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 009 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://bioadaptives.com/role/StockholdersEquity STOCKHOLDERS' EQUITY Notes 9 false false R10.htm 010 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://bioadaptives.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 10 false false R11.htm 011 - Disclosure - SUBSEQUENT EVENT Sheet http://bioadaptives.com/role/SubsequentEvent SUBSEQUENT EVENT Notes 11 false false R12.htm 012 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Policies) Sheet http://bioadaptives.com/role/Summaryofsignificantpoliciespolicies SUMMARY OF SIGNIFICANT POLICIES (Policies) Policies 12 false false R13.htm 013 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Tables) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables SUMMARY OF SIGNIFICANT POLICIES (Tables) Tables http://bioadaptives.com/role/SummaryOfSignificantPolicies 13 false false R14.htm 014 - Disclosure - DESCRIPTION OF BUSINESS AND HISTORY (Detail Textuals) Sheet http://bioadaptives.com/role/DescriptionOfBusinessAndHistoryDetailTextuals DESCRIPTION OF BUSINESS AND HISTORY (Detail Textuals) Details http://bioadaptives.com/role/DescriptionOfBusinessAndHistory 14 false false R15.htm 015 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetails SUMMARY OF SIGNIFICANT POLICIES (Details) Details http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables 15 false false R16.htm 016 - Disclosure - SUMMARY OF SIGNIFICANT POLICIES (Details Textual) Sheet http://bioadaptives.com/role/SummaryOfSignificantPoliciesDetailsTextual SUMMARY OF SIGNIFICANT POLICIES (Details Textual) Details http://bioadaptives.com/role/SummaryOfSignificantPoliciesTables 16 false false R17.htm 017 - Disclosure - GOING CONCERN (Detail Textuals) Sheet http://bioadaptives.com/role/GOINGCONCERNDetailTextuals GOING CONCERN (Detail Textuals) Details http://bioadaptives.com/role/GoingConcern 17 false false R18.htm 018 - Disclosure - STOCKHOLDERS'EQUITY (Detail Textuals) Sheet http://bioadaptives.com/role/STOCKHOLDERSEQUITYDetailTextuals STOCKHOLDERS'EQUITY (Detail Textuals) Details 18 false false R19.htm 019 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) Sheet http://bioadaptives.com/role/RELATEDPARTYTRANSACTIONSDetailTextuals RELATED PARTY TRANSACTIONS (Detail Textuals) Details http://bioadaptives.com/role/RelatedPartyTransactions 19 false false R20.htm 020 - Disclosure - SUBSEQUENT EVENT (Details) Sheet http://bioadaptives.com/role/SUBSEQUENTEVENTDetails SUBSEQUENT EVENT (Details) Details http://bioadaptives.com/role/SubsequentEvent 20 false false All Reports Book All Reports bdpt-20160630.xml bdpt-20160630.xsd bdpt-20160630_cal.xml bdpt-20160630_def.xml bdpt-20160630_lab.xml bdpt-20160630_pre.xml true true ZIP 39 0001640334-16-001576-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001640334-16-001576-xbrl.zip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end